Is GLOW approved or legal?

No. GLOW and its components (GHK-Cu, BPC-157, TB-500) are not FDA-approved medicines. They are sold for research use only and are not approved for human consumption. Legal status varies by country, and product purity from research suppliers is not guaranteed.

What dose and half-life does GLOW have?

There is no established clinical dose. Anecdotal community protocols describe small daily subcutaneous injections (often ~2 mg GHK-Cu) on cycles of several weeks. Component plasma half-lives are roughly in the hours range, though tissue effects may last longer; the blend itself has not been formally studied. This is informational only, not dosing advice.

Is there human evidence that GLOW works?

Only partially. GHK-Cu has real human clinical data, mostly from topical skin and wound-healing studies. BPC-157 and TB-500 are supported mainly by animal and lab studies, and no controlled human trial has tested the GLOW combination.

How is GLOW typically administered?

Community use is most often subcutaneous injection after reconstitution with bacteriostatic water; GHK-Cu is also widely used topically in cosmetics. The blend has not been validated for any route in controlled human studies.

What are the main safety concerns?

Injection-site reactions, unknown long-term safety for injected BPC-157 and TB-500, possible copper-load concerns with high GHK-Cu exposure, and risks from non-sterile self-injection or impure research-grade product. Consult a qualified clinician before any use.

Blend

GLOW

Also known as: GLOW protocol, GLOW peptide blend

Research-only blend of GHK-Cu, BPC-157 and TB-500 marketed for skin and tissue repair; component data is mostly preclinical.

Last updated July 11, 2026

Buy GLOW

What's in this blend

GHK-Cu — 50mg (details)
BPC-157 — 10mg (details)
TB-500 — 10mg (details)

Overview

GLOW is a fixed-ratio combination of three research peptides: the copper tripeptide GHK-Cu (typically 50 mg), BPC-157 (10 mg) and TB-500 (a thymosin beta-4 fragment, 10 mg). It is promoted in the peptide community for skin rejuvenation, wound healing and connective-tissue recovery, with the rationale that the three components act on complementary repair pathways. It is sold and discussed strictly as a research chemical, not an approved drug. The evidence base is uneven and component-specific rather than blend-specific. GHK-Cu has the strongest human data, mostly from topical cosmetic studies and surgical/diabetic wound trials. BPC-157 and TB-500 are supported almost entirely by animal and in-vitro work, with little to no completed human efficacy trial data. No controlled human trial has ever evaluated the GLOW combination itself. Because GLOW pairs a topically-validated cosmetic peptide with two injectable peptides that lack human approval, claims about systemic or injected use should be read cautiously. Any combined benefit is theoretical synergy, not a demonstrated outcome of the blend. GLOW is not FDA-approved, is not a medicine, and the content here is informational only, not medical advice or an instruction to use it.

How it works

The blend combines three mechanisms. GHK-Cu is a copper-binding tripeptide that delivers copper into cells, stimulates collagen, elastin and glycosaminoglycan synthesis, modulates matrix metalloproteinases and their inhibitors (TIMP-1/2), and broadly up- and down-regulates thousands of genes involved in tissue remodeling, DNA repair and antioxidant defense. BPC-157, a synthetic pentadecapeptide derived from a gastric protein, is reported in animal models to promote angiogenesis, fibroblast outgrowth and migration (FAK-paxillin pathway), upregulate growth-hormone receptor expression and modulate nitric oxide signaling. TB-500 is a fragment of thymosin beta-4 whose core function is G-actin sequestration; through cytoskeletal regulation it is associated in preclinical work with cell migration, angiogenesis, anti-inflammatory signaling and an anti-fibrotic Ac-SDKP action. The proposed combined rationale: GHK-Cu rebuilds extracellular matrix, BPC-157 supports blood supply to the repair site, and TB-500 biases healing toward functional tissue over scar.

Researched effects

Clinical Improved skin elasticity, firmness and reduced fine lines (GHK-Cu, topical cosmetic use)
Clinical Supported reepithelialization in some diabetic and surgical wound-healing studies (GHK-Cu)
Preclinical Increased collagen, elastin and glycosaminoglycan synthesis
Preclinical Accelerated tendon, ligament and muscle healing (BPC-157)
Preclinical Enhanced angiogenesis and cell migration supporting tissue repair (TB-500)
Preclinical Reduced scarring and anti-fibrotic effect (TB-500 / Ac-SDKP)
Anecdotal Faster recovery from injury, improved skin glow and joint comfort with the combined blend

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans for the GLOW blend or for injected BPC-157/TB-500. Human clinical data for GHK-Cu come almost entirely from topical cosmetic formulations and wound-care studies, not from a standardized systemic dose of this combination.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or an instruction to use. Community guides and dosing calculators describe reconstituting a roughly 70 mg vial (about 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500) with 2.5-3 mL bacteriostatic water and self-administering a small daily subcutaneous injection, commonly cited around 10-20 insulin units (about 0.1-0.2 mL) into the abdomen or thigh, targeting roughly 2 mg GHK-Cu per dose. Reported cycling is typically 6-12 weeks on followed by 3-8 weeks off, or stepping down to 2-3 times weekly for maintenance. These figures come from vendor guides, dosing-calculator sites and peptide forums rather than controlled trials; reported protocols vary widely and product purity is unverified.

Half-life: Component-dependent: GHK-Cu and TB-500 plasma half-lives are on the order of hours (tissue effects may persist longer); BPC-157's human half-life is not well characterized. Overall: ~hours, blend not formally studied.
Routes: subcutaneous, topical

Safety & side effects

GLOW is not FDA-approved and is sold for research use only; product identity, purity and dosing accuracy from research suppliers are not guaranteed. GHK-Cu has a long record of good tolerability in topical/cosmetic use. BPC-157 and TB-500 lack robust human safety data, so injected use carries unknown long-term risk. Commonly reported issues are injection-site reactions (redness, swelling, irritation), and excess copper exposure from GHK-Cu is a theoretical concern with high or prolonged systemic dosing. Sterility and dosing errors are real risks with self-injection. Anyone considering use should consult a qualified clinician; this is not medical advice.

Research summary

The evidence for GLOW is the sum of its parts, and those parts are very unevenly studied. GHK-Cu is the best supported: multiple placebo-controlled human studies (typically 40-70 subjects over ~12 weeks) show improvements in skin firmness, elasticity and wrinkles with topical use, and some human wound-healing studies report improved reepithelialization in diabetic and surgical wounds. Its mechanisms-collagen/matrix remodeling, broad gene regulation, copper delivery-are well characterized in vitro and in animals. BPC-157 and TB-500, by contrast, rest almost entirely on preclinical work. BPC-157 shows consistent tendon, ligament, muscle and gut healing across more than two decades of rodent studies, but there are essentially no completed randomized human efficacy trials and only minimal pilot safety data. TB-500's actin-sequestration mechanism and regenerative effects are documented in animal models of cardiac, wound, tendon and neurological injury, with no published completed human efficacy trials for the 17-amino-acid fragment. Crucially, no controlled study has evaluated the GLOW blend as a combination, by injection or otherwise. The proposed synergy is biologically plausible but unproven in humans. Honest framing: GHK-Cu has genuine clinical (mostly topical) support, while the injectable components and the blend as a whole are experimental. GLOW should be treated as research-use-only, and community dosing protocols are anecdotal references, not validated regimens.

FAQ

Is GLOW approved or legal?: No. GLOW and its components (GHK-Cu, BPC-157, TB-500) are not FDA-approved medicines. They are sold for research use only and are not approved for human consumption. Legal status varies by country, and product purity from research suppliers is not guaranteed.
What dose and half-life does GLOW have?: There is no established clinical dose. Anecdotal community protocols describe small daily subcutaneous injections (often ~2 mg GHK-Cu) on cycles of several weeks. Component plasma half-lives are roughly in the hours range, though tissue effects may last longer; the blend itself has not been formally studied. This is informational only, not dosing advice.
Is there human evidence that GLOW works?: Only partially. GHK-Cu has real human clinical data, mostly from topical skin and wound-healing studies. BPC-157 and TB-500 are supported mainly by animal and lab studies, and no controlled human trial has tested the GLOW combination.
How is GLOW typically administered?: Community use is most often subcutaneous injection after reconstitution with bacteriostatic water; GHK-Cu is also widely used topically in cosmetics. The blend has not been validated for any route in controlled human studies.
What are the main safety concerns?: Injection-site reactions, unknown long-term safety for injected BPC-157 and TB-500, possible copper-load concerns with high GHK-Cu exposure, and risks from non-sterile self-injection or impure research-grade product. Consult a qualified clinician before any use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.